Akorn has struck a deal to divest its consumer healthcare business to Prestige Consumer Healthcare for $230m in cash. The company said the transaction – which is expected to close in the third quarter of 2021 – would allow it to invest in optimizing its prescription business.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?